At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
tafamidisdrug
Likely dose
tafamidis 61 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy
In Brief
An observational study evaluating tafamidis for Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartMar 2023
Primary CompletionMay 2023
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartMar 8, 2023
Primary CompletionMay 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.6 years ago
Interventions
tafamidisdrug
80 or 61 milligrams (mg)